1. Home
  2. IQV vs ALC Comparison

IQV vs ALC Comparison

Compare IQV & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IQV
  • ALC
  • Stock Information
  • Founded
  • IQV 1982
  • ALC 1945
  • Country
  • IQV United States
  • ALC Switzerland
  • Employees
  • IQV N/A
  • ALC N/A
  • Industry
  • IQV Biotechnology: Commercial Physical & Biological Resarch
  • ALC Ophthalmic Goods
  • Sector
  • IQV Health Care
  • ALC Health Care
  • Exchange
  • IQV Nasdaq
  • ALC Nasdaq
  • Market Cap
  • IQV 35.7B
  • ALC 41.0B
  • IPO Year
  • IQV 2013
  • ALC N/A
  • Fundamental
  • Price
  • IQV $197.47
  • ALC $84.37
  • Analyst Decision
  • IQV Strong Buy
  • ALC Strong Buy
  • Analyst Count
  • IQV 17
  • ALC 14
  • Target Price
  • IQV $255.88
  • ALC $102.53
  • AVG Volume (30 Days)
  • IQV 1.2M
  • ALC 775.5K
  • Earning Date
  • IQV 02-12-2025
  • ALC 02-25-2025
  • Dividend Yield
  • IQV N/A
  • ALC 0.31%
  • EPS Growth
  • IQV 27.98
  • ALC 156.61
  • EPS
  • IQV 7.62
  • ALC 2.34
  • Revenue
  • IQV $15,315,000,000.00
  • ALC $9,761,000,000.00
  • Revenue This Year
  • IQV $3.67
  • ALC $5.43
  • Revenue Next Year
  • IQV $4.53
  • ALC $6.42
  • P/E Ratio
  • IQV $25.89
  • ALC $35.74
  • Revenue Growth
  • IQV 3.10
  • ALC 5.25
  • 52 Week Low
  • IQV $187.62
  • ALC $74.30
  • 52 Week High
  • IQV $261.73
  • ALC $101.10
  • Technical
  • Relative Strength Index (RSI)
  • IQV 45.36
  • ALC 46.68
  • Support Level
  • IQV $194.06
  • ALC $82.31
  • Resistance Level
  • IQV $207.72
  • ALC $83.68
  • Average True Range (ATR)
  • IQV 4.74
  • ALC 1.04
  • MACD
  • IQV 0.12
  • ALC 0.14
  • Stochastic Oscillator
  • IQV 27.90
  • ALC 59.71

About IQV IQVIA Holdings Inc.

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

About ALC Alcon Inc.

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Share on Social Networks: